Michelle C. Fox, MD

Merck & Co., Inc.

Disclosure(s): Merck & Co., Inc.: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-344) Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-cell Counts in People Living with HIV
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-364) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-368) Population Pharmacokinetic Analysis of Islatravir and the Impact of Intrinsic Factors in Participants with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-369) Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-377) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-389) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations or M184I/V in Proviral DNA
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET